Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Stauber, RE; Fauler, G; Rainer, F; Leber, B; Posch, A; Streit, A; Spindelboeck, W; Stadlbauer, V; Kessler, HH; Mangge, H.
Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus.
Wien Klin Wochenschr. 2017; 129(21-22):848-851 Doi: 10.1007/s00508-017-1268-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Stauber Rudolf
Co-Autor*innen der Med Uni Graz
Fauler Günter
Kessler Harald
Leber Bettina
Mangge Harald
Rainer Florian
Spindelböck Walter Johann
Stadlbauer-Köllner Vanessa

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Direct acting antiviral (DAA)-based treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir (OBV/PTV/r ± DSV) is highly effective in HCV genotype 1 or 4 infection and well-tolerated with only few side effects. However, pruritus has been observed in several trials in up to 20% of patients and seems to be unique for this DAA combination. The aim of this preliminary study was to investigate the effect of OBV/PTV/r ± DSV on bile acid levels and to correlate them to the emergence of pruritus during treatment. Twenty patients with chronic hepatitis C genotype 1 or 4 were treated for 12 or 24 weeks with OBV/PTV/r ± DSV with or without ribavirin. Side effects including pruritus were assessed every 4 weeks during treatment or on demand. Blood was collected in fasting state at baseline and at treatment week 4 for determination of bile acid concentrations by high-resolution mass spectrometry. Pruritus developed in 5 out of 20 patients during the first 4 weeks of DAA treatment. Pruritus was self-limiting during DAA treatment in 4 patients while one patient required cholestyramine treatment and responded well. Total bile acid levels increased approximately 4‑fold by treatment week 4. Pruritus observed during OBV/PTV/r ± DSV treatment of chronic hepatitis C is associated with increased on-treatment serum bile acid levels, possibly due to ritonavir-induced alterations of bile acid transport.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Anilides - adverse effects
Anilides - therapeutic use
Bile Acids and Salts - blood
Carbamates - adverse effects
Carbamates - therapeutic use
Drug Therapy, Combination -
Female -
Genotype -
Hepacivirus - drug effects
Hepacivirus - genetics
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - drug therapy
Humans -
Macrocyclic Compounds - adverse effects
Macrocyclic Compounds - therapeutic use
Male -
Middle Aged -
Pruritus - blood
Pruritus - chemically induced
Ritonavir - adverse effects
Ritonavir - therapeutic use
Sulfonamides - adverse effects
Sulfonamides - therapeutic use
Uracil - adverse effects
Uracil - analogs & derivatives
Uracil - therapeutic use

Find related publications in this database (Keywords)
Chronic hepatitis C
Direct acting antivirals
Bile acids
© Med Uni Graz Impressum